In vivo assessment of herb-drug interactions: Possible utility of a pharmacogenetic approach?

Molecular Nutrition and Food Research

Volumn 52, Issue 7, 2008, Pages 799-809

  Tomlinson, Brian ^a,c   Hu, Miao ^a   Lee, Vivian W Y ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Chinese University of Hong Kong   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cytochrome P450 enzymes; Drug transporters; Ethnic differences; Herb drug interactions; Pharmacogenetic

Indexed keywords

CYTOCHROME P450; PLANT EXTRACT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG EFFECT; ETHNIC GROUP; GENETIC POLYMORPHISM; GENETICS; HERB DRUG INTERACTION; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; PHARMACOGENETICS; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CYTOCHROME P-450 ENZYME SYSTEM; ETHNIC GROUPS; HERB-DRUG INTERACTIONS; HUMANS; NEOPLASMS; PHARMACOGENETICS; PLANT EXTRACTS; POLYMORPHISM, GENETIC;

EID: 53249149715     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200700454     Document Type: Review

References (140)

1. Tomlinson, B., Chan, T. Y., Chan, J. C., Critchley, J. A., But, P. P., Toxicity of complementary therapies: an eastern perspective. J. Clin. Pharmacol. 2000, 40, 451-456.
2. Richardson, M. A., Sanders, T., Palmer, J. L., Greisinger, A., Singletary, S. E., Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J. Clin. Oncol. 2000, 18, 2505-2514.
3. Sparber, A., Wootton, J. C., Bauer, L., Curt, G., et al., Use of complementary medicine by adult patients participating in HIV/AIDS clinical trials. J. Altern. Complement. Med. 2000, 6, 415-422.
4. Chavez, M. L., Jordan, M. A., Chavez, P. I., Evidence-based drug - herbal interactions. Life Sci. 2006, 78, 2146-2157.
5. Hu, Z., Yang, X., Ho, P. C., Chan, S. Y., et al., Herb-drug interactions: A literature review. Drugs 2005, 65, 1239-1282.
6. Mills, E., Wu, P., Johnston, B. C., Gallicano, K., et al., Natural health product-drug interactions: A systematic review of clinical trials. Ther. Drug Monit. 2005, 27, 549-557.
7. Barnes, J., Pharmacovigilance of herbal medicines: A UK perspective. Drug Saf. 2003, 26, 829-851.
8. De Smet, P. A., Herbal medicine in Europe-relaxing regulatory standards. N. Engl. J. Med. 2005, 352, 1176-1178.
9. Fugh-Berman, A., Ernst, E., Herb-drug interactions: Review and assessment of report reliability. Br. J. Clin. Pharmacol. 2001, 52, 587-595.
10. Moon, Y. J., Wang, X., Morris, M. E., Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism. Toxicol. In Vitro 2006, 20, 187-210.
11. Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., et al., The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 2003, 31, 815-832.
12. Huang, S. M., Lesko, L. J., Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: What havewe learned? J. Clin. Pharmacol. 2004, 44, 559-569.
13. Yuan, R., Madani, S., Wei, X. X., Reynolds, K., Huang, S. M., Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab. Dispos. 2002, 30, 1311-1319.
14. Streetman, D. S., Bertino, J. S., Jr., Nafziger, A. N., Phenotyping of drug-metabolizing enzymes in adults: A review of invivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000, 10, 187-216.
15. Frye, R. F., Matzke, G. R., Adedoyin, A., Porter, J. A., Branch, R. A., Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin. Pharmacol. Ther. 1997, 62, 365-376.
16. Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., et al., Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin. Pharmacol. Ther. 2002, 72, 276-287.
17. Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., et al., Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St. John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005, 22, 525-539.
18. Andersen, V., Pedersen, N., Larsen, N. E., Sonne, J., Larsen, S., Intestinal first pass metabolism of midazolam in liver cirrhosis - effect of grapefruit juice. Br. J. Clin. Pharmacol. 2002, 54, 120-124.
19. Yin, O. Q., Tomlinson, B., Waye, M. M., Chow, A. H., Chow, M. S., Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004, 14, 841-850.
20. Ho, R. H., Kim, R. B., Transporters and drug therapy: Implications for drug disposition and disease. Clin. Pharmacol. Ther. 2005, 78, 260-277.
21. Shitara, Y., Horie, T., Sugiyama, Y., Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 2006, 27, 425-446.
22. Zhang, L., Strong, J. M., Qiu, W., Lesko, L. J., Huang, S. M., Scientific perspectives on drug transporters and their role in drug interactions. Mol. Pharm. 2006, 3, 62-69.
23. Omari, A. A., Murry, D. J., Pharmacogenetics of the cytochrome P450 enzyme system: Review of current knowledge and clinical significance. J. Pharm. Pract. 2007, 20, 206-218.
24. Streetman, D. S., Clinical pharmacogenetics of the major adenosine triphosphate-binding cassette and solute carrier drug transporters. J. Pharm. Pract. 2007, 20, 219-233.
25. Choudhuri, S., Klaassen, C. D., Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 2006, 25, 231-259.
26. Christensen, M., Tybring, G., Mihara, K., Yasui-Furokori, N., et al., Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin. Pharmacol. Ther. 2002, 71, 141-152.
27. Uno, T., Shimizu, M., Yasui-Furukori, N., Sugawara, K., Tateishi, T., Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br. J. Clin. Pharmacol. 2006, 61, 309-314.
28. Yasui-Furukori, N., Saito, M., Uno, T., Takahata, T., et al., Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J. Clin. Pharmacol. 2004, 44, 1223-1229.
29. Yasui-Furukori, N., Takahata, T., Nakagami, T., Yoshiya, G., et al., Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br. J. Clin. Pharmacol. 2004, 57, 487-494.
30. Pedersen, R. S., Damkier, P., Brosen, K., The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. Br. J. Clin. Pharmacol. 2006, 62, 682-689.
31. Zhou, H. H., Anthony, L. B., Wood, A. J., Wilkinson, G. R., Induction of polymorphic 49-hydroxylation of S-mephenytoin by rifampicin. Br. J. Clin. Pharmacol. 1990, 30, 471-475.
32. Feng, H. J., Huang, S. L., Wang, W., Zhou, H. H., The induction effect of rifampicin on activity of mephenytoin 49-hydroxylase related to M1 mutation of CYP2C19 and gene dose. Br. J. Clin. Pharmacol. 1998, 45, 27-29.
33. Andersson, T., Cederberg, C., Edvardsson, G., Heggelund, A., Lundborg, P., Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin. Pharmacol. Ther. 1990, 47, 79-85.
34. Ishizaki, T., Chiba, K., Manabe, K., Koyama, E., et al., Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin. Pharmacol. Ther. 1995, 58, 155-164.
35. Kosuge, K., Jun, Y., Watanabe, H., Kimura, M., et al., Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Drug Metab. Dispos. 2001, 29, 1284-1289.
36. Johnson, J. A., Zineh, I., Puckett, B. J., McGorray, S. P., et al., Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin. Pharmacol. Ther. 2003, 74, 44-52.
37. Johnson, J. A., Burlew, B. S., Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab. Dispos. 1996, 24, 350-355.
38. Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., et al., Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 2005, 352, 2285-2293.
39. Veenstra, D. L., You, J. H., Rieder, M. J., Farin, F. M., et al., Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics 2005, 15, 687-691.
40. Izzat, M. B., Yim, A. P., El-Zufari, M. H., A taste of Chinese medicine! Ann. Thorac. Surg. 1998, 66, 941-942.
41. Tam, L. S., Chan, T. Y., Leung, W. K., Critchley, J. A., Warfarin interactions with Chinese traditional medicines: Danshen and methyl salicylate medicated oil. Aust. N. Z. J. Med. 1995, 25, 258.
42. Yu, C. M., Chan, J. C., Sanderson, J. E., Chinese herbs and warfarin potentiation by 'danshen'. J. Intern. Med. 1997, 241, 337-339.
43. Hedenmalm, K., Lindh, J. D., Sawe, J., Rane, A., Increased liability of tramadol-warfarin interaction in individuals with mutations in the cytochrome P450 2D6 gene. Eur. J. Clin. Pharmacol. 2004, 60, 369-372.
44. Malhi, H., Atac, B., Daly, A. K., Gupta, S., Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. Postgrad. Med. J. 2004, 80, 107-109.
45. Bailey, D. G., Spence, J. D., Munoz, C., Arnold, J. M., Interaction of citrus juices with felodipine and nifedipine. Lancet 1991, 337, 268-269.
46. Lown, K. S., Bailey, D. G., Fontana, R. J., Janardan, S. K., et al., Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 1997, 99, 2545-2553.
47. Bailey, D. G., Malcolm, J., Arnold, O., Spence, J. D., Grapefruit juice-drug interactions. Br. J. Clin. Pharmacol. 1998, 46, 101-110.
48. Malhotra, S., Bailey, D. G., Paine, M. F., Watkins, P. B., Seville orange juice-felodipine interaction: Comparison with dilute grapefruit juice and involvement of furocoumarins. Clin. Pharmacol. Ther. 2001, 69, 14-23.
49. Dahan, A., Altman, H., Food-drug interaction: Grapefruit juice augments drug bioavailability - mechanism, extent and relevance. Eur. J. Clin. Nutr. 2004, 58, 1-9.
50. Veronese, M. L., Gillen, L. P., Burke, J. P., Dorval, E. P., et al., Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J. Clin. Pharmacol. 2003, 43, 831-839.
51. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., Guengerich, F. P., Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270, 414-423.
52. Ozdemir, V., Kalow, W., Tang, B. K., Paterson, A. D., et al., Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method. Pharmacogenetics 2000, 10, 373-388.
53. Ball, S. E., Scatina, J., Kao, J., Ferron, G. M., et al., Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin. Pharmacol. Ther. 1999, 66, 288-294.
54. Lamba, J. K., Lin, Y. S., Schuetz, E. G., Thummel, K. E., Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 2002, 54, 1271-1294.
55. Xie, H. G., Wood, A. J., Kim, R. B., Stein, C. M., Wilkinson, G. R., Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004, 5, 243-272.
56. Daly, A. K., Significance of the minor cytochrome P450 3A isoforms. Clin. Pharmacokinet. 2006, 45, 13-31.
57. Kuehl, P., Zhang, J., Lin, Y., Lamba, J., et al., Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 2001, 27, 383-391.
58. Lin, Y. S., Dowling, A. L., Quigley, S. D., Farin, F. M., et al., Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol. 2002, 62, 162-172.
59. Lilja, J. J., Kivisto, K. T., Neuvonen, P. J., Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin. Pharmacol. Ther. 1999, 66, 118-127.
60. Kantola, T., Kivisto, K. T., Neuvonen, P. J., Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. 1998, 63, 397-402.
61. Lilja, J. J., Kivisto, K. T., Neuvonen, P. J., Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin. Pharmacol. Ther. 1998, 64, 477-483.
62. Ducharme, M. P., Provenzano, R., Dehoorne-Smith, M., Edwards, D. J., Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br. J. Clin. Pharmacol. 1993, 36, 457-459.
63. Ducharme, M. P., Warbasse, L. H., Edwards, D. J., Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin. Pharmacol. Ther. 1995, 57, 485-491.
64. Benton, R. E., Honig, P. K., Zamani, K., Cantilena, L. R., Woosley, R. L., Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin. Pharmacol. Ther. 1996, 59, 383-388.
65. Spence, J. D., Drug interactions with grapefruit: Whose responsibility is it to warn the public? Clin. Pharmacol. Ther. 1997, 61, 395-400.
66. Ozdemir, M., Aktan, Y., Boydag, B. S., Cingi, M. I., Musmul, A., Interaction between grapefruit juice and diazepam in humans. Eur. J. Drug Metab. Pharmacokinet. 1998, 23, 55-59.
67. Pearce, R. E., Rodrigues, A. D., Goldstein, J. A., Parkinson, A., Identification of the human P450 enzymes involved in lansoprazole metabolism. J. Pharmacol. Exp. Ther. 1996, 277, 805-816.
68. Uno, T., Yasui-Furukori, N., Takahata, T., Sugawara, K., Tateishi, T., Lack of significant effect of grapefruit juice on the pharmacokinetics of lansoprazole and its metabolites in subjects with different CYP2C19 genotypes. J. Clin. Pharmacol. 2005, 45, 690-694.
69. Miura, M., Kagaya, H., Tada, H., Uno, T., et al., Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole. Xenobiotica 2006, 36, 95-102.
70. Tassaneeyakul, W., Vannaprasaht, S., Yamazoe, Y., Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice. Br. J. Clin. Pharmacol. 2000, 49, 139-144.
71. Dresser, G. K., Bailey, D. G., The effects of fruit juices on drug disposition: A new model for drug interactions. Eur. J. Clin. Invest. 2003, 2, 10-16.
72. Becquemont, L., Verstuyft, C., Kerb, R., Brinkmann, U., et al., Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin. Pharmacol. Ther. 2001, 70, 311-316.
73. Dresser, G. K., Bailey, D. G., Leake, B. F., Schwarz, U. I., et al., Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. 2002, 71, 11-20.
74. Dresser, G. K., Kim, R. B., Bailey, D. G., Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: Possible role of organic anion transporting polypeptides. Clin. Pharmacol. Ther. 2005, 77, 170-177.
75. Schwarz, U. I., Seemann, D., Oertel, R., Miehlke, S., et al., Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin. Pharmacol. Ther. 2005, 77, 291-301.
76. Soons, P. A., Breimer, D. D., Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects. Br. J. Clin. Pharmacol. 1991, 32, 11-16.
77. Tomlinson, B., Chow, M. S., Stereoselective interaction of manidipine and grapefruit juice: A new twist on an old tale. Br. J. Clin. Pharmacol. 2006, 61, 529-532.
78. Vincent, J., Harris, S. I., Foulds, G., Dogolo, L. C., et al., Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. Br. J. Clin. Pharmacol. 2000, 50, 455-463.
79. Josefsson, M., Zackrisson, A. L., Ahlner, J., Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur. J. Clin. Pharmacol. 1996, 51, 189-193.
80. Josefsson, M., Ahlner, J., Amlodipine and grapefruit juice. Br. J. Clin. Pharmacol. 2002, 53, 405; author reply 406.
81. Dresser, G. K., Schwarz, U. I., Wilkinson, G. R., Kim, R. B., Coordinate induction of both cytochrome P4503A and MDR1 by St. John's wort in healthy subjects. Clin. Pharmacol. Ther. 2003, 73, 41-50.
82. Ernst, E., The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann. Intern. Med. 2002, 136, 42-53.
83. Markowitz, J. S., Donovan, J. L., DeVane, C. L., Taylor, R. M., et al., Effect of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003, 290, 1500-1504.
84. Arold, G., Donath, F., Maurer, A., Diefenbach, K., et al., No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St. John's wort extract. Planta Med. 2005, 71, 331-337.
85. Andren, L., Andreasson, A., Eggertsen, R., Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia. Eur. J. Clin. Pharmacol. 2007, 63, 913-916.
86. Eggertsen, R., Andreasson, A., Andren, L., Effects of treatment with a commercially available St. John's Wort product (Movina(R)) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin. Scand. J. Prim. Health Care 2007, 25, 154-159.
87. Xie, R., Tan, L. H., Polasek, E. C., Hong, C., et al., CYP3A and P-glycoprotein activity induction with St. John's Wort in healthy volunteers from 6 ethnic populations. J. Clin. Pharmacol. 2005, 45, 352-356.
88. Komoroski, B. J., Zhang, S., Cai, H., Hutzler, J. M., et al., Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab. Dispos. 2004, 32, 512-518.
89. Wang, L. S., Zhu, B., Abd El-Aty, A. M., Zhou, G., et al., The influence of St. John's Wort on CYP2C19 activity with respect to genotype. J. Clin. Pharmacol. 2004, 44, 577-581.
90. Chan, K., Lo, A. C., Yeung, J. H., Woo, K. S., The effects of Danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats. J. Pharm. Pharmacol. 1995, 47, 402-406.
91. Davis, E. A., Morris, D. J., Medicinal uses of licorice through the millennia: the good and plenty of it. Mol. Cell. Endocrinol. 1991, 78, 1-6.
92. Ojima, M., Satoh, K., Gomibuchi, T., Itoh, N., et al., The inhibitory effects of glycyrrhizin and glycyrrhetinic acid on the metabolism of cortisol and prednisolone - in vivo and in vitro studies. Nippon Naibunpi Gakkai Zasshi 1990, 66, 584-596.
93. Izzo, A. A., Di Carlo, G., Borrelli, F., Ernst, E., Cardiovascular pharmacotherapy and herbal medicines: The risk of drug interaction. Int. J. Cardiol. 2005, 98, 1-14.
94. Andersson, T., Flockhart, D. A., Goldstein, D. B., Huang, S. M., et al., Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests. Clin. Pharmacol. Ther. 2005, 78, 559-581.
95. Zanger, U. M., Raimundo, S., Eichelbaum, M., Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 369, 23-37.
96. Bertilsson, L., Dahl, M. L., Dalen, P., Al-Shurbaji, A., Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 2002, 53, 111-122.
97. Xie, H. G., Kim, R. B., Wood, A. J., Stein, C. M., Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 815-850.
98. Hiratsuka, M., Sasaki, T., Mizugaki, M., Genetic testing for pharmacogenetics and its clinical application in drug therapy. Clin. Chim. Acta 2006, 363, 177-186.
99. Beutler, E., Gelbart, T., Demina, A., Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl. Acad. Sci. USA 1998, 95, 8170-8174.
100. Lampe, J. W., Bigler, J., Horner, N. K., Potter, J. D., UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 1999, 9, 341-349.
101. Jada, S. R., Xiaochen, S., Yan, L. Y., Xiaoqiang, X. et al., Pharmacogenetics of SLCO1B1: Haplotypes, htSNPs and hepatic expression in three distinct Asian populations. Eur. J. Clin. Pharmacol. 2007, 63, 555-563.
102. Dai, D., Zeldin, D. C., Blaisdell, J. A., Chanas, B. et al., Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001, 11, 597-607.
103. Nakajima, M., Fujiki, Y., Noda, K., Ohtsuka, H. et al., Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab. Dispos. 2003, 31, 687-690.
104. Lee, S. S., Jeong, H. E., Yi, J. M., Jung, H. J., et al., Identification and functional assessment of BCRP polymorphisms in a Korean population. Drug Metab. Dispos. 2007, 35, 623-632.
105. Inatomi, H., Katoh, T., Kawamoto, T., Matsumoto, T., NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese. Int. J. Urol. 1999, 6, 446-454.
106. He, L. J., Yu, Y. M., Qiao, F., Liu, J. S., et al., Genetic polymorphisms of N-acetyltransferase 2 and colorectal cancer risk. World J. Gastroenterol. 2005, 11, 4268-4271.
107. Liou, Y. H., Lin, C. T., Wu, Y. J., Wu, L. S., The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population. J. Hum. Genet. 2006, 51, 857-863.
108. Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., et al., A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. 1999, 274, 37161-37168.
109. Iida, A., Saito, S., Sekine, A., Mishima, C., et al., Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteins. J. Hum. Genet. 2001, 46, 668-683.
110. Nozawa, T., Nakajima, M., Tamai, I., Noda, K., et al., Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): Allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 2002, 302, 804-813.
111. Pasanen, M. K., Backman, J. T., Neuvonen, P. J., Niemi, M., Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur. J. Clin. Pharmacol. 2006, 62, 409-415.
112. Fromm, M. F., The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv. Drug Deliv. Rev. 2002, 54, 1295-1310.
113. Tang, K., Ngoi, S. M., Gwee, P. C., Chua, J. M., et al., Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002, 12, 437-450.
114. Zamber, C. P., Lamba, J. K., Yasuda, K., Farnum, J., et al., Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003, 13, 19-28.
115. Mizuarai, S., Aozasa, N., Kotani, H., Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int. J. Cancer 2004, 109, 238-246.
116. Itoda, M., Saito, Y., Soyama, A., Saeki, M., et al., Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: An association between single nucleotide polymorphisms in the 59-untranslated region and exon 28. Drug Metab. Dispos. 2002, 30, 363-364.
117. Ito, K., Oleschuk, C. J., Westlake, C., Vasa, M. Z., et al., Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J. Biol. Chem. 2001, 276, 38108-38114.
118. Ito, S., Ieiri, I., Tanabe, M., Suzuki, A., et al., Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/ cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001, 11, 175-184.
119. Niemi, M., Arnold, K. A., Backman, J. T., Pasanen, M. K., et al., Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet. Genomics 2006, 16, 801-808.
120. Ho, R. H., Choi, L., Lee, W., Mayo, G., et al., Effect of drug transporter genotypes on pravastatin disposition in European-and African-American participants. Pharmacogenet. Genomics 2007, 17, 647-656.
121. Lee, C. G., Chong, S. S., Lee, E. J. D., Pharmacogenetics of the human MDR1 multidrug transporter. Current Pharmacogenomimcs 2004, 2, 1-11.
122. Ozawa, S., Soyama, A., Saeki, M., Fukushima-Uesaka, H., et al., Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab. Pharmacokinet. 2004, 19, 83-95.
123. Piscitelli, S. C., Burstein, A. H., Welden, N., Gallicano, K. D., Falloon, J., The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin. Infect. Dis. 2002, 34, 234-238.
124. Gallicano, K., Foster, B., Choudhri, S., Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br. J. Clin. Pharmacol. 2003, 55, 199-202.
125. Mauro, V. F., Mauro, L. S., Kleshinski, J. F., Khuder, S. A., et al., Impact of ginkgo biloba on the pharmacokinetics of digoxin. Am. J. Ther. 2003, 10, 247-251.
126. Johne, A., Schmider, J., Brockmoller, J., Stadelmann, A. M., et al., Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum), J. Clin. Psychopharmacol. 2002, 22, 46-54.
127. Wang, Z., Gorski, J. C., Hamman, M. A., Huang, S. M., et al., The effects of St. John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin. Pharmacol. Ther. 2001, 70, 317-326.
128. Bauer, S., Stormer, E., Johne, A., Kruger, H., et al., Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St. John's wort in renal transplant patients. Br. J. Clin. Pharmacol. 2003, 55, 203-211.
129. Breidenbach, T., Hoffmann, M. W., Becker, T., Schlitt, H., Klempnauer, J., Drug interaction of St. John's wort with cyclosporin. Lancet 2000, 355, 1912.
130. Breidenbach, T., Kliem, V., Burg, M., Radermacher, J., et al., Profound drop of cyclosporin A whole blood trough levels caused by St. John's wort (Hypericum perforatum). Transplantation 2000, 69, 2229-2230.
131. Frye, R. F., Fitzgerald, S. M., Lagattuta, T. F., Hruska, M. W., Egorin, M. J., Effect of St. John's wort on imatinib mesylate pharmacokinetics. Clin. Pharmacol. Ther. 2004, 76, 323-329.
132. Mai, I., Stormer, E., Bauer, S., Kruger, H., et al., Impact of St. John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol. Dial. Transplant. 2003, 18, 819-822.
133. Piscitelli, S. C., Burstein, A. H., Chaitt, D., Alfaro, R. M., Falloon, J., Indinavir concentrations and St. John's wort. Lancet 2000, 355, 547-548.
134. Smith, P., Bullock, J. M., Booker, B. M., Haas, C. E., et al., The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004, 24, 1508-1514.
135. Sugimoto, K., Ohmori, M., Tsuruoka, S., Nishiki, K., et al., Different effects of St. John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin. Pharmacol. Ther. 2001, 70, 518-524.
136. Johne, A., Brockmoller, J., Bauer, S., Maurer, A., et al., Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum). Clin. Pharmacol. Ther. 1999, 66, 338-345.
137. Wang, Z., Hamman, M. A., Huang, S. M., Lesko, L. J., Hall, S. D., Effect of St. John's wort on the pharmacokinetics of fexofenadine. Clin. Pharmacol. Ther. 2002, 71, 414-420.
138. Bano, G., Raina, R. K., Zutshi, U., Bedi, K. L., et al., Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur. J. Clin. Pharmacol. 1991, 41, 615-617.
139. Cheng, T. O., Warfarin danshen interaction. Ann. Thorac. Surg. 1999, 67, 894.
140. Piscitelli, S. C., Formentini, E., Burstein, A. H., Alfaro, R., et al., Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 2002, 22, 551-556.